In one paragraphArticle in The Journal of infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from itWhat it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
17 authors.
Claire P SmithDepartment of Epidemiology, University of North Carolina Gillings School of Public Health, Chapel Hill, North Carolina, USA.ORCID 0000-0003-1069-9460 Justin LesslerDepartment of Epidemiology, University of North Carolina Gillings School of Public Health, Chapel Hill, North Carolina, USA.
Sonia T HegdeDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.ORCID 0000-0001-6426-0096 Taufiqur R BhuiyanInfectious Diseases Division, International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh.ORCID 0000-0003-3755-4763 Md Taufiqul IslamInfectious Diseases Division, International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh.ORCID 0000-0003-1584-484X Faisal AhmmedInfectious Diseases Division, International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh.
Fahima ChowdhuryInfectious Diseases Division, International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh.ORCID 0000-0002-7082-0720 Ashraful I KhanInfectious Diseases Division, International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh.
Regina C LaRocqueDivision of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA.ORCID 0000-0003-4558-0339 Richelle C CharlesDivision of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA.ORCID 0000-0002-8881-1849 Stephen B CalderwoodDivision of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA.ORCID 0000-0002-2083-7153 Edward T RyanDivision of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA.ORCID 0009-0005-0169-394X Jason B HarrisDivision of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA.
Andrew S AzmanDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Firdausi QadriInfectious Diseases Division, International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh.
Kirsten E WiensDepartment of Epidemiology and Biostatistics, Temple University Barnett College of Public Health, Philadelphia, Pennsylvania, USA.ORCID 0000-0003-4093-4054 Funding
Immune Responses to Vibrio cholerae infection and vaccination in HaitiR01AI099243 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI HARRIS, JASON B, IVERS, LOUISE C. · 2012 to 2022
$7.9MO-Specific Polysaccharide Responses and CholeraR37AI106878 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Edward T. Ryan · 2020 to 2026
$5.1MAntibody mediated protective immunity against choleraR01AI137164 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI CHARLES, RICHELLE C, HARRIS, JASON B · 2018 to 2022
$3.9MO-Specific Polysaccharide Responses and CholeraR01AI106878 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI RYAN, EDWARD T. · 2014 to 2018
$3.7MO-Specific Polysaccharide Responses and CholeraR56AI106878 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI RYAN, EDWARD T. · 2013 to 2020
$843kHumoral and adaptive immune responses study in Vibrio cholerae infectionK43TW010362 · FIC · INTERNATIONAL CTR/DIARRHOEAL DIS RES · PI BHUIYAN, MD TAUFIQUR RAHMAN · 2016 to 2020
$359kThe role of unobserved cholera: implications for prevention and controlK22AI168389 · NIAID · TEMPLE UNIV OF THE COMMONWEALTH · PI WIENS, KIRSTEN E · 2023 to 2024
$270kFIC NIH HHS K43 TW010362icddr,bNational Institute of Allergy and Infectious Diseases AI099243National Institute of Allergy and Infectious Diseases AI106878National Institute of Allergy and Infectious Diseases AI137164National Institute of Allergy and Infectious Diseases AI168389National Institute of Allergy and Infectious Diseases TW010362NIAID NIH HHS K22 AI168389NIAID NIH HHS R01 AI099243NIAID NIH HHS R01 AI106878NIAID NIH HHS R01 AI137164NIAID NIH HHS R37 AI106878NIAID NIH HHS R56 AI106878NIH HHS
6 · The paper itselfAbstract
backgroundIn Bangladesh, cholera treatment focuses on acute watery diarrhea in symptomatic cases at health facilities, though asymptomatic infections are common. Understanding the role of asymptomatic infections in transmission is crucial for designing appropriate control strategies in this setting.
methodsWe utilized data from household studies conducted in Dhaka, Bangladesh, during 2006-2018 where a symptomatic confirmed cholera case and their household contacts were followed for 30 days. Vibriocidal antibodies, bacteriological culture, and symptom histories were collected at multiple time points. We used a hidden Markov model to estimate risk of infection from intra-household and extra-household (ie, community and environmental) sources and to quantify relative risk of transmission from symptomatic and asymptomatic infected household contacts.
resultsEstimated daily risk of intra-household infection from a symptomatic individual to another household member was 2.6% (95% credible interval [CrI], .4%-5.6%) and from an asymptomatic infected individual to another household member was 1.6% (95% CrI, .2%-4.5%). We found no significant differences in probability of infection from asymptomatic compared to symptomatic individuals (odds ratio, 0.60 [95% CrI, .11-3.23]). We estimated that daily risk of infection from extra-household sources during follow-up was 1.0% (95% CrI, .7%-1.4%).
conclusionsMitigation measures focused solely on treatment of symptomatic cholera cases may be insufficient to prevent transmission in a household. This supports use of interventions that reduce risk of transmission irrespective of symptoms, such as prophylactic antibiotic treatment for household members, vaccination, and/or providing safe water and hygiene kits following a confirmed household or community case.
Indexed as
Asymptomatic InfectionsCholeraAdolescentAdultBangladeshChildChild, PreschoolFamily CharacteristicsFemaleHumansInfantMaleMarkov ChainsMiddle AgedVibrio choleraeYoung Adultasymptomatic infectioncholerahidden Markov modelhousehold transmissionVibrio cholerae
Identifiers
PMID42246165
PMCPMC13431773
What OpenQuestion holds
Textmetadata
Read underepoch 390